MO if the bloom-dm data shows marginal efficacy lorquess is dead, irrespective of whether ARNA can explain the tumor data, because its a long term use drug and the marginal efficacy is not worth the risk.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.